4.8 Article

Prevalence of smoldering multiple myeloma based on nationwide screening

期刊

NATURE MEDICINE
卷 -, 期 -, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41591-022-02183-6

关键词

-

向作者/读者索取更多资源

This study investigated the epidemiological characteristics of smoldering multiple myeloma (SMM) in the general population of Iceland. The prevalence of SMM in individuals 40 years or older was found to be 0.53%, with higher rates in men (0.67%) than in women (0.39%). The high prevalence of SMM has important implications for future treatment policies in multiple myeloma.
Smoldering multiple myeloma (SMM) is an asymptomatic precursor to multiple myeloma. Here we define the epidemiological characteristics of SMM in the general population in Iceland. The iStopMM study (ClinicalTrials.gov ID: NCT03327597) is a nationwide screening study for multiple myeloma precursors where all residents in Iceland 40 years or older were invited to participate. SMM was defined as 10-60% bone marrow plasma cells and/or monoclonal (M) protein concentration >= 3 g dl(-1), in the absence of myeloma-defining events. Of the 80,759 who gave informed consent to participate, 75,422 (93%) were screened. The prevalence of SMM in the total population was 0.53% (95% confidence interval (CI) = 0.49- 0.57%) in individuals 40 years or older. In men and women, the prevalence of SMM was 0.67% (95% CI = 0.62-0.73%) and 0.39% (95% CI = 0.35-0.43%), respectively; it increased with age in both sexes. For the 193 individuals with SMM, median age was 70 years (range 44-92 years) and 60% were males. The mean M protein concentration of individuals with SMM was 0.62 g dl(-1)(range 0.01-3.5 g dl(-1)) and 73% had 11-20% bone marrow plasma cell infiltration. The high prevalence of SMM has implications for future treatment policies in multiple myeloma as the evidence supporting treatment initiation at the SMM stage is emerging.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据